Melinta Therapeutics Inc (MLNT, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Melinta Therapeutics Inc is a commercial-stage biopharmaceutical company. It is developing antibiotic, Baxdela (delafloxacin), for the treatment of adults with serious skin infections known as acute bacterial skin and skin structure infections. Melinta Therapeutics Inc has a market cap of $63.250 million; its shares were traded at around $5.64 with and P/S ratio of 0.43.
For the last quarter Melinta Therapeutics Inc reported a revenue of $34.1 million, compared with the revenue of $1.72 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $96.4 million, an increase of 184.8% from last year. For the last five years Melinta Therapeutics Inc had an average revenue decline of 0% a year.
The reported loss per diluted share was $17.12 for the year, compared with the loss per share of $45.25 in the previous year. The Melinta Therapeutics Inc had an operating margin of -132.24%, compared with the operating margin of -233.1% a year before. The 10-year historical median operating margin of Melinta Therapeutics Inc is -469.86%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, Melinta Therapeutics Inc has the cash and cash equivalents of $81.8 million, compared with $128.4 million in the previous year. The long term debt was $110.5 million, compared with $39.6 million in the previous year. Melinta Therapeutics Inc has a financial strength rank of 4 (out of 10).
At the current stock price of $5.64, Melinta Therapeutics Inc is traded at 98.8% discount to its historical median P/S valuation band of $478.47. The P/S ratio of the stock is 0.43, while the historical median P/S ratio is 36.99. The stock lost 90.15% during the past 12 months.
For the complete 20-year historical financial data of MLNT, click here.
